<DOC>
	<DOCNO>NCT00771992</DOCNO>
	<brief_summary>The effect surfactant protein D native alter condition investigate immune cell derive bronchoalveolar lavage patient allergic asthma follow segmental allergen challenge . The goal study elucidate pro- versus anti-inflammatory function SP-D molecule identify motifs SP-D treatment potential allergic asthma .</brief_summary>
	<brief_title>Ex Vivo Effect Surfactant Protein D Pulmonary Immune Cells Derived From Bronchoalveolar Lavage After Segmental Allergen Challenge Patients With Asthma</brief_title>
	<detailed_description>Following baseline BAL , allergen ( 3× ) saline ( 1× ) instill four different lung segment first bronchoscopy . After 24 hour second bronchoscopy BAL collect challenged segment harvest invaded cell in-vitro experimentation . In addition , bronchial biopsy epithelial brush take assess degree local inflammation bronchial mucosa study activation airway epithelium follow allergen challenge .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Pulmonary Surfactants</mesh_term>
	<mesh_term>Pulmonary Surfactant-Associated Protein D</mesh_term>
	<criteria>Able willing give write informed consent Physician diagnosis mild asthma accord GINA guideline ( 7 ) age 1855 year Nonsmokers history le 1 packyear nonsmoker least last five year FEV1 ≥ 80 % predict , FEV1/FVC ≥ 70 % Positive skin prick test grass mix D. pteronyssinus within 12 month prior screen visit Positive response inhale methacholine ( ≤ 8 mg/mL ) Positive response incremental inhale allergen challenge house dust mite allergen grass pollen allergen Women consider inclusion : pregnant , confirmed pregnancy test , nurse nonchild bear potential ( i.e . physiologically incapable become pregnant , include female premenarchial postmenopausal , document proof hysterectomy tubal ligation , meet clinical criterion menopause amenorrhoeic 1 year prior screen visit ) childbearing potential use highly effective method contraception entire study ( vasectomized partner , sexual abstinence lifestyle female complete abstinence intercourse two week prior study least 72 hour end study , implant , injectables , combine oral contraceptive , hormonal IUDs , doublebarrier method , i.e . double combination IUD , condom spermicidal gel , diaphragm , sponge , cervical cap ) Available complete study measurement History upper low respiratory tract infection four week prior inform consent visit Past present disease , judge investigator , may affect outcome study . These disease include , limited , cardiovascular disease , malignancy , hepatic disease , renal disease , hematological disease , neurological disease , psychiatric disease , endocrine disease , infectious disease , inflammatory disease , pulmonary disease ( include confine chronic bronchitis , emphysema , tuberculosis , bronchiectasis cystic fibrosis ) . Clinically significant pathological finding safety laboratory test Regular intake medication short act inhaled beta agonist , paracetamol pain relief , birth control medication , hormonal replacement therapy , dietary vitamin supplement Specific Immunotherapy ( SIT ) within two year prior study Use antiinflammatory medication include systemic inhaled corticosteroid within last four week Any history lifethreatening asthma , define asthma episode require intubation and/or associate hypercapnea , respiratory arrest hypoxic seizure . Suspected hypersensitivity ingredient medication line bronchoscopy ( bronchodilator , sedatives local anesthetic ) Conditions factor , would make subject unlikely able undergo bronchoscopy incremental allergen challenge History drug alcohol abuse Suspected inability understand protocol requirement , instruction studyrelated restriction , nature , scope , possible consequence study . Participation clinical trial 30 day prior enrolment Segmental allergen challenge three month prior treatment Risk noncompliance study procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Asthma GINA 1</keyword>
</DOC>